Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2026 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2026 Earnings Call Transcript
ARCT - Arcturus Therapeutics Holdings Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$22.50
DETAILS
HIGH:
$25.00
LOW:
$20.00
MEDIAN:
$22.50
CONSENSUS:
$22.50
UPSIDE:
220.06%
Stock News
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to a loss of $0.52 per share a year ago.
Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the quarter ended March 31, 2026, and provided corporate updates. “Arcturus continues to advance its rare disease therapeutics portfolio. We have initiated enrollment of our 12‑week CF Phase 2 study in the first quarter of 2026, earlier.
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for the quarter ended March 31, 2026 after the market close on Thursday, May 7th and will also host a conference call and webcast at 4:30 pm Eastern Time on May 7, 2026. Arcturus Therapeutics First Quarter 2026 Earnings.
Diversify Advisory Services LLC Sells 115,500 Shares of Arcturus Therapeutics Holdings Inc. $ARCT
Diversify Advisory Services LLC reduced its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) by 88.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,000 shares of the biotechnology company's stock after selling 115,500 shares
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Cathie Wood added to her stakes in Circle Internet Group, Arcturus Therapeutics, and 10x Genomics on Tuesday. Circle tumbled on Tuesday following reports that regulatory tightening may be on the way for its stablecoin domain.
Arcturus Therapeutics Refocuses on Rare Disease mRNA Pipeline After COVID Vaccine Success at ROTH Conf
Arcturus Therapeutics (NASDAQ: ARCT) CEO Joe Payne told investors at the 38th Annual ROTH Conference that the company is refocusing on rare disease programs after gaining approvals for its COVID-19 vaccine in more than 30 countries. Payne said Arcturus had initiated a rare disease strategy for messenger RNA (mRNA) medicines before the pandemic and is now
These Are the Only 3 Stocks That Cathie Wood Bought Last Week
Cathie Wood added to her stakes in Figma, Arcturus Therapeutics, and 10x Genomics last week. Analysts see Figma's growth slowing dramatically in the next two years, but an 83% drop from last year's high makes it a compelling consideration.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $29.50 Average Target Price from Brokerages
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT - Get Free Report) has earned an average rating of "Moderate Buy" from the thirteen research firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, eight have issued a buy recommendation and one
Arcturus Therapeutics Teases 12-Week Phase 2 CF Study After Well-Tolerated Inhaled mRNA Dosing
Arcturus Therapeutics (NASDAQ: ARCT) Chief Executive Officer Joe Payne told investors at the Leerink Partners Global Healthcare Conference that the company has advanced its inhaled messenger RNA cystic fibrosis (CF) program through three Phase 2 cohorts and is preparing to initiate a longer 12-week study designed to better evaluate lung function outcomes. CF program: 28-day cohorts
Arcturus Therapeutics to Attend Upcoming Investor Conference
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will participate in the following investor conference, in Miami, Florida: Leerink Partners 2026 Global Healthcare Conference (Fireside Chat) Wednesday, March 11, 2026 (11:20 a.m. ET) Webcast link can be found under Investor Relations/Events secti.
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2025 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2025 Earnings Call Transcript
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to a loss of $1.11 per share a year ago.
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the fourth quarter and fiscal year 2025, and provided corporate updates. “Arcturus continues to progress its rare disease therapeutic portfolio. We look forward to aligning with regulators on our clinical development strategy for the orn.
Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that it will release its financial results for the quarter and year ended December 31, 2025 after the market close on Tuesday, March 3 and will also host a conference call and webcast at 4:30 p.m. Eastern Time on March 3.
Arcturus Therapeutics Spotlights Inhaled mRNA CF Phase 2b Plan, FDA Talks for OTC Program at Summit
Arcturus Therapeutics (NASDAQ: ARCT) used a presentation at Guggenheim's 2026 Emerging Outlook Biotech Summit to highlight upcoming milestones for its messenger RNA (mRNA) rare disease pipeline, with CEO Joe Payne emphasizing progress in inhaled mRNA for cystic fibrosis (CF) and an intravenously dosed liver-targeted program for ornithine transcarbamylase (OTC) deficiency. Positioning as an mRNA medicines company
Arcturus Therapeutics: Two Catalysts, One Runway, And A Stock Priced For Failure
Arcturus Therapeutics now centers on ARCT-032 (cystic fibrosis) and ARCT-810 (OTC deficiency), with Covid assets as secondary cash support. ARCT is priced as a busted biotech with optionality; cash runway extends to 2028, but clinical and regulatory risks remain significant. ARCT-032's 12-week trial and ARCT-810's FDA alignment are key re-rating catalysts; both programs face pivotal data and regulatory endpoints.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the thirteen research firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have given
Price Targets
'2026 will be a stock-moving year for ArthroCare (ARTC)'; PT Lowered at Piper Sandler
$25.00
(was $7.42)
Yasmeen Rahimi
·
Piper Sandler
Arcturus Therapeutics initiated with a Buy at Roth Capital
$20.00
(was $7.59)
Roth Capital
Arcturus Therapeutics price target lowered to $54 from $63 at Leerink
$54.00
(was $18.51)
Lili Nsongo
·
Leerink Partners
Arcturus Therapeutics initiated with an Outperform at Scotiabank
$32.00
(was $11.82)
Greg Harrison
·
Scotiabank
BTIG Reiterates Buy Rating on Arcturus Therapeutics (ARCT)
$48.00
(was $14.55)
Thomas Shrader
·
BTIG
Arcturus Therapeutics (ARCT) PT Raised to $74 at Canaccord Genuity
$74.00
(was $3.02)
Whitney Ijem
·
Canaccord Genuity
Arcturus Therapeutics price target lowered to $72 from $86 at Canaccord
$72.00
(was $3.20)
Whitney Ijem
·
Canaccord Genuity
H.C. Wainwright Reiterates Buy Rating on Arcturus Therapeutics (ARCT)
$60.00
(was $3.38)
Ed Arce
·
H.C. Wainwright
Piper Sandler Reiterates Overweight Rating on Arcturus Therapeutics (ARCT)
$140.00
(was $5.64)
Yasmeen Rahimi
·
Piper Sandler
Arcturus Therapeutics price target lowered to $86 from $87 at Canaccord
$86.00
(was $3.83)
Whitney Ijem
·
Canaccord Genuity
Laidlaw Reiterates Buy Rating on Arcturus Therapeutics (ARCT)
$79.00
(was $4.83)
Yale Jen
·
Laidlaw
Barclays Upgrades Arcturus Therapeutics (ARCT) to Equalweight
$25.00
(was $21.69)
Gena Wang
·
Barclays
Goldman Sachs Maintains Sell on Arcturus Therapeutics, Lowers Price Target to $14
$14.00
(was $13.55)
Goldman Sachs
UPDATE: Arcturus Therapeutics (ARCT) PT Raised to $30 at Goldman Sachs (CORRECTION)
$30.00
(was $36.23)
Madhu Kumar
·
Goldman Sachs